XenoPort Inc

XenoPort — Technical Presentation (September 2015)

21 slides from XenoPort's technical presentation, Sep 15, 2015

  1. Slide 1: XP23829 Phase 2 Psoriasis Trial Preliminary Topline Data Presentation

    Exhibit 99.1 XP23829 PRELIMINARY SEPTEMBER © COPYRIGHT PHASE 15,2015 TOPLINE 22015 PSORIASIS XENOPORT, DATA TRIAL PRESENTATION INC. ALL RIGHTS RESERVED.

  2. Slide 2: Safe Harbor Disclaimer

    SAFE These opportunities of XP23829 that submission to important product will development Phase FDA’s XenoPort’s the PAGE these XP23829 quarter could be3slides HARBOR 2review successful, development statements, or | XP093 and factors, accelerate other ended operations; tois and and for that process

  3. Slide 3: Key Observations from Preliminary Results of Phase 2 Clinical Trial

    KEYprimary Met Efficacy post PAGE treatment OBSERVATIONS 3 |still XP093endpoint improving First TOPLINE demonstration ofat FROM %end change PRESENTATION ofPRELIMINARY treatment that in PASI a MMF (week with |prodrug 15 800 RESULTS 12) SEPTEMBER QD Low other and incidence OF than 400XP23829 BID 2015

  4. Slide 4: XP23829 Phase 2 Psoriasis Trial Design

    XP23829 Titration Screening/ Study and Number Primary PAGE safety Design 4 Endpoint |of 400 XP093 PHASE study Post-Treatment Sites Subjects mg Randomized, in 33 TOPLINE BID The 2subjects sites PSORIASIS 200Titration percent randomized inWeek United double-blind, with PRESENTATION change 800 moderate

  5. Slide 5: Key Eligibility Criteria

    KEYbe Chronic PASI sPGA BSA Candidate May Excluded PAGE (body ELIGIBILITY (Psoriasis (Static 5either plaque-type | XP093 subjects for surface Physician’s phototherapy treatment Area TOPLINE with area) CRITERIA psoriasis and inadequate naïve affected Global Severity and/or PRESENTATION diagnosed or A

  6. Slide 6: Key Baseline Demographics

    KEY XP QD Mean Moderate % Prior Median Biologic Weight PAGE Patients 400mg (N=48) Systemic DEMOGRAPHICS PASI BSA 6(kg) Body | XP093 sPGA with XP (%) Score QD 90.95 800mg 33.3% 22.9% (N=53) 66.7% TOPLINE 18.3 95.30 39.6% XP 24.3 18.4 69.8% BID 92.05 /400 BASELINE %PRESENTATION 17.7 (N=46) 37.0% mg 69

  7. Slide 7: Primary Endpoint: Percent Change from Baseline in PASI Score at Week 12

    PRIMARY BASELINE XP QD Least Mean p-value Modified PAGE 400mg (N=48) Squares -38.1 70.066 | XP093 Intent XP ENDPOINT: -48.2 (N=53) IN0.001 800mg PASI toTOPLINE -50.7 Treat BID <0.001 SCORE QD -25.0 (mITT) (N=46) PERCENT XPPRESENTATION AT 400population (N=47) WEEK mgCHANGE Placebo 12and| FROM 15 Mixe

  8. Slide 8: Least Squares Mean Percent Change from Baseline in PASI Score Over Time

    LEAST mITT PAGE population, 8 SQUARES | XP093 TOPLINE MMRM MEAN PERCENT PRESENTATION CHANGE | 15 FROM SEPTEMBER BASELINE 2015IN PASI SCORE OVER TIME

  9. Slide 9: Effect of Prior Biologic Use on Percent Change from Baseline in PASI Score

    EFFECT No Biologic Prior QD Least P-value Mean mITT PAGEPrior (N=16) Biologic Squares population, 9 0.691 0.011 |QD XP OF XP093 QD 400mg PRIOR (N=32) <0.001 0.492 -48.1 -17.4 XP(N=21) TOPLINE MMRM 400mg -56.1 -31.9 XP 0.245 BIOLOGIC QD <0.001 800mg BID (N=32) XP -59.1 -38.1 PRESENTATION (N=17) 800mg

  10. Slide 10: PASI Responders Analysis at Week 12

    *PAGE PASI LOCF* 40 50 60 Subjects Percent 21.7 of 30 13.6 10 0P PASI-50 mITT lacebo 38.0 9.1 12.8 RESPONDERS population 20 39.1 Imputation 10400 Last 36.2 PASI-60 14.0 mg Observation | XP093QD PASI-70 800 ANALYSIS TOPLINEmg Carried PASI-75 QD 400 Forward ATmg WEEK BID 12| 15 SEPTEMBER 2015 PRESENTA

  11. Slide 11: PASI Responders Analysis at Week 12: No Prior Biologic Subpopulation

    PASI LOCF 50 50.0 60 Subjects 40 44.8 of Percent 20.7 10 12.1 0P PASI-50 mITT PAGE lacebo 23.3 48.4 9.1RESPONDERS population 11 Imputation 20 400 30 PASI-60 | XP093 19.4 mg QDPASI-70 TOPLINE 800 ANALYSIS mgPASI-75 QD PRESENTATION 400 ATmg WEEK BID 12| NO 15 SEPTEMBER PRIOR BIOLOGIC 2015 SUBPOPULATIO

  12. Slide 12: Safety Overview

    SAFETY No subjects One PAGE deaths subject 12with OVERVIEW | or XP093 with life-threatening serious acute enterocolitis; an TOPLINE abdominal TEAEs cholecystitis; –adverse PRESENTATION All possibly hernia; recovered possibly events not related related (AEs) related to| 15 XP23829 toNo SEPTEMBER XP23

  13. Slide 13: Most Common Treatment Emergent AEs

    *PAGE MOST XP QD Diarrhea Nausea Pain Abdominal Vomiting Headache Flushing* 400mg (N=49) 1 13 (2.0%) COMMON 6Not 11 (12.2%) 3|24XP093 XP (6.1%) QD (4.1%) (22.4%) (8.2%) >10% 7800mg (12.7%) (N=55) 4TOPLINE 7(>10%) but 3(7.3%) (12.7%) 22 (5.5%) XP a(40.0%) BID 11 common 400 TREATMENT 10 (22.9%) 52(N=4

  14. Slide 14: Treatment Emergent AEs Leading to Permanent Drug Withdrawal

    TREATMENT LEADING XP QD Diarrhea Nausea Abdominal Vomiting Headache PAGE 400mg (N=49) 14 0 201|1XP093 (4.1%) XP TO 2(2.0%) Pain QD (2.0%) (4.2%) 800mg EMERGENT PERMANENT (N=55) 1 TOPLINE 3(2.0%) 10(5.5%) 2(1.8%) 2XP (4.2%) (4.2%) BID 2400 7(3.6%) 0(N=48) AES PRESENTATION (14.6%) 0mg 1DRUG (2.1%) Pla

  15. Slide 15: Maximum Lymphocyte Grades at Any Visit

    MAXIMUM XP QD No All Grade PAGEsubjects 400mg (N=49) 115or 2 3 1: 2: 3: 4: 23<200 <1000-800 <800-500 <500-200 |(4.1%) (6.1%) XP093 XP 4QD below were 0LYMPHOCYTE 800mg 0cells/mm3 (N=55) 025Grade TOPLINE 0700 cells/mm3 (9.1%) (3.6%) cells/mm3 XP cells/mm3 BID 1 400 or 7 (2.1%) 1 (14.6%) less (N=48) PR

  16. Slide 16: Key Observations from Preliminary Results of Phase 2 Clinical Trial

    KEYprimary Met Efficacy post PAGE treatment OBSERVATIONS 16still | XP093 endpoint improving FirstTOPLINE demonstration ofat FROM %end change PRESENTATION ofPRELIMINARY treatment that in PASI a MMF (week withprodrug | 800 15 RESULTS 12) SEPTEMBER QD Low other and incidence OF than 400XP23829 BID DMF

  17. Slide 17: Thank You

    THANK © COPYRIGHT YOU 2015 XENOPORT, INC. ALL RIGHTS RESERVED.

  18. Slide 18: Appendix

    PAGE 18 | XP093 TOPLINE PRESENTATION | 15 SEPTEMBER 2015 Appendix

  19. Slide 19: Historical Phase 3 Psoriasis Study Data

    HISTORICAL Conducted Median at PASI Adverse Flushing Diarrhea Abdominal Headache Nausea No PAGE week indication 50 75 19 10% PASI 16 65% 39% Events 31% 42% |11% XP093 (did at Pain vs. 10 score vs of vs. TECFIDERA vs. not 0% 12% 14% 1% drop-out sites 9% TOPLINE 6% describe reduction placebo placebo p

  20. Slide 20: XP23829 PASI Responders Analysis at Week 12: LOCF and Observed

    XP23829 LOCF 21.7 30 13.6 Observed 50 50.0 53.6 60 Subjects 40 of Percent 21.9 0P 10 11.8 PASI-50 mITT PAGE lacebo 30 38.0 9.1 46.9 12.8 population 20 Imputation 20 39.1 400 36.2 32.1 PASI-60 14.0 |PASI case XP093 17.6 mg–RESPONDERS 18.8 QD Completed PASI-70 TOPLINE 800 mgPASI-75 12 QD PRESENTATION

  21. Slide 21: XP23829 PASI Responders Analysis: No Prior Biologic, LOCF and Observed

    XP23829 LOCF 50.0 44.8 20.7 12.1 Observed 63.6 60 Subjects 40 50 of Percent 0P 10 12.5 PASI-50 mITT PAGE lacebo 23.3 30 48.4 9.1 59.1 62.5 27.3 population 21 Imputation 20 400 30 31.8 PASI-60 |PASI Case XP093 19.4 16.7 mg31.3 –RESPONDERS QD Completed PASI-70 TOPLINE 800 mgPASI-75 12 QD PRESENTATION

Xenoport — Technical Presentation (September 2015) on 6ix